At last week's ESHG annual meeting, three quality assessment providers discussed best practice guidelines and results from a pilot NIPT quality assessment scheme.
In a report made public this week, the French National Authority for Health recommended NIPT if first semester screening indicated a risk between 1 in 51 and 1 in 1,000.
For the year ended March 31, the Manchester, UK-based provider of noninvasive prenatal testing reported more than £3.1 million ($4 million) in revenue.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
The company said that Illumina and Sequenom's NIPT patents are not present in the Middle East, allowing it to sell its Iona test unimpeded.
The G-BA commissioned a contractor to prepare an evidence report by early 2018 and to gather information for patients by early 2019.
The results of the Harvard-led study suggest that the immune system struggles to infiltrate and attack tumors with more aneuploidy.
The collaborators will explore the use of cell-free DNA for preimplantation genetic testing.
Going forward, Natera said it will market its Panorama NIPT assay and carrier screening test Horizon directly to physicians.
LifeCodexx's PrenaTest will be available to women in Malaysia, Singapore, Thailand, Brunei, Vietnam, the United Arab Emirates, and elsewhere in the Middle East.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.